You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
337 Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCD 1703 POCHI

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020162012
Dec 20202407
Jan 20212602
Feb 20212605
Mar 20216209
Apr 20212806
May 2021509
Jun 2021008
Jul 20210012
Aug 2021004
Sep 2021008
Oct 202134024
Nov 202122013
Dec 20213803
Jan 20223405
Feb 20224607
Mar 20223801
Apr 20226205
May 20223202
Jun 20223603
Jul 20224001
Aug 20223204
Sep 20223405
Oct 20224003
Nov 20223203
Dec 20224605
Jan 20236202
Feb 20235202
Mar 20233602
Apr 20234004
May 20235204
Jun 20233003
Jul 20235803
Aug 20234805
Sep 20234000
Oct 20235004
Nov 20238004
Dec 20236405
Jan 20242401
Feb 20243301
Mar 20246003
Apr 20247009
May 20243400
Jun 20249308
Jul 2024118010
Aug 20247901
Sep 20248705
Oct 20245605
Nov 20247402
Dec 20245004
Jan 20255404
Feb 20251601
Mar 2025006
Apr 2025007
May 2025004
Jun 2025003
Total23590278